Market Access

A check on the evolving challenges and potential solutions in steering future market adoption of curative-intended treatments.

Following a year which saw a 143% increase in launched biosimilars in the US, here are three reasons why payers will drive adoption further in 2021.

Following the announcement of his new role, Pharm Exec had the chance to speak with Daniel Schroen, PhD about his past experience as well as the landscape of the therapeutic development industry.

Therapeutic companies that work with rare diseases must take early steps to build relationships with patients, caregivers, and HCPs.

A look at best-practice approaches to aligning the strategy and design of hub service models with preparations for market entry of a new therapy.

While gene therapies continue to revolutionize healthcare, uncertainty from commercialization issues still looms large.

Amid pandemic, rely on the fundamentals.

Looking at four building blocks of success, Wolfram Lux and Simone Seiter investigate what it takes to win and be successful when commercializing an orphan drug

A look into the complex battle between pharmaceutical manufacturers and payers for balance between medication access and budget management.

Knowing that product reimbursement affects performance and varies by geography, this article proposes the use of Reimbursement Benchmark Share (RBS) to quantify the influence of reimbursement on a product’s performance.

With new access levers emerging, positioning products will require a shift form the traditional launch playbook.

Proposals around the globe seek to ensure access to any promising treatments.

Examining the key learnings from BCG’s 2019 benchmark study-and the capabilities uncovered that will be critical to future performance.

Banks Bourne of Tanner Pharma Group talks about the organization's role in delivering access initiatives for products not commercially available in many parts of the world.

Three product launch trends driven by emerging biopharma.

Renewed education efforts by employers, however, are slowly helping them take back decision-making reins in their engagements with pharma.

Lundbeck executive Taj Bhardwaj talks about the differing mindsets necessary to lead local and global-level market access strategy in pharma-and how his current company is committed to stay in the fight to advance new treatments and break down stigmas in mental health.

Exploring the roadmap for US-based, R&D-focused biopharma companies seeking to successfully penetrate product markets and reach patients in Europe.

Industry working group identifies the value characteristics that may, collectively, become part of a shared approach to valuing pharmaceutical treatments.

Amy Mahery, last month appointed Global Head of Market Access and Pricing of the healthcare business of Merck KGaA, Darmstadt, Germany, discusses her key priorities and how she will draw on her multi-faceted industry experience to approach the challenges ahead.

The industry’s quest to get a handle on the cost-shift implications of these new programs and the risks for patient access and pharma’s bottom line.

With employers and the public scrutinizing drug prices like never before, rebates-long at the center of pharma’s market access strategy-may be losing their luster, writes Amber Gilbert.

Pharm Exec’s annual feature profiling a selection of notable biopharma brands focuses this year on new beginnings and new promise-spotlighting five products with compelling product launch stories that tie strongly with the industry’s broader and evolving market-entry landscape.

Amid the noteworthy product launches profiled this year by Pharm Exec are four more therapy trailblazers worth highlighting.

Four takeaway messages from the Zolgensma pricing storm